C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis

详细信息    查看全文

• 作者：Bo Zhou ; Bin Shu ; Jue Yang ; Jing Liu ; Tao Xi ; Yingying Xing
• 关键词：CRP ; IL ; 6 ; Colorectal cancer ; Risk ; Meta ; analysis
• 刊名：Cancer Causes and Control
• 出版年：2014
• 出版时间：October 2014
• 年：2014
• 卷：25
• 期：10
• 页码：1397-1405
• 全文大小：844 KB
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-0 CrossRef
  2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-0 CrossRef
  3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-67 CrossRef
  4. Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807-816 CrossRef
  5. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854-62 CrossRef
  6. Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E et al (2011) Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg 15:576-83 CrossRef
  7. Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639-45 CrossRef
  8. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-613 CrossRef
  9. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A et al (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 106:1340-350 CrossRef
  10. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-54 CrossRef
  11. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP et al (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123:1133-140 CrossRef
  12. Heikkil? K, Harris R, Lowe G, Rumley A, Yarnell J et al (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15-6 CrossRef
  13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-88 CrossRef
  14. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301-309
  15. Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6:40-7
  16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-558 CrossRef
  17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-34 CrossRef
  18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51(264-69):W264 CrossRef
  19. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW (2010) Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 39:699-09 CrossRef
  20. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N et al (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case–control study. Am J Epidemiol 177:3-3 CrossRef
  21. Helzlsouer KJ, Erlinger TP, Platz EA (2006) C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42:704-07 CrossRef
  22. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010) C-reactive protein and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 102:202-06 CrossRef
  23. Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K et al (2013) Plasma C-reactive protein, genetic risk score, and risk of common cancers in the atherosclerosis risk in communities study. Cancer Causes Control 24:2077-087 CrossRef
  24. Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176:335-38 CrossRef
  25. Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15:369-73 CrossRef
  26. Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222-26 CrossRef
  27. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K et al (2005) Serum IL-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11:1639-643
  28. Dymicka-Piekarska V, Matowicka-Karna J, Gryko M, Kemona-Chetnik I, Kemona H (2007) Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 120:585-90 CrossRef
  29. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH et al (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97:1266-270 CrossRef
  30. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y et al (2008) Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98:540-44 CrossRef
  31. Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Kedra B, Lukaszewicz M et al (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46:1423-428 CrossRef
  32. Kwon KA, Kim SH, Oh SY, Lee S, Han JY et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10:203 CrossRef
  33. Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU et al (2011) Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 104:51-9 CrossRef
  34. Cooney RV, Chai W, Franke AA, Wilkens LR, Kolonel LN et al (2013) C-reactive protein, lipid-soluble micronutrients, and survival in colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 22:1278-288 CrossRef
  35. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585-90 CrossRef
  36. Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M et al (2005) Colorectal cancer and serum C-reactive protein levels: a case–control study nested in the JACC Study. J Epidemiol 15(Suppl 2):S185–S189 CrossRef
  37. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142:425-32 CrossRef
  38. Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC et al (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14:2413-418 CrossRef
  39. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15:381-84 CrossRef
  40. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC et al (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol 24:5216-222 CrossRef
  41. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S et al (2006) Plasma C-reactive protein and risk of colorectal cancer in a nested case–control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 15:690-95 CrossRef
  42. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S et al (2006) A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66:2483-487 CrossRef
  43. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27:2217-224 CrossRef
  44. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB et al (2010) Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case–control study within the European prospective investigation into cancer and nutrition. Am J Epidemiol 172:407-18 CrossRef
  45. Chan AT, Ogino S, Giovannucci EL, Fuchs CS (2011) Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140:799-08 CrossRef
  46. Lee S, Choe JW, Kim HK, Sung J (2011) High-sensitivity C-reactive protein and cancer. J Epidemiol 21:161-68 CrossRef
  47. Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011) Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 20:297-07 CrossRef
  48. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G et al (2011) Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 20:428-37 CrossRef
  49. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M et al (2012) Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 72:3029-037 CrossRef
  50. Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y et al (2013) Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 132:2648-658 CrossRef
  51. Song M, Wu K, Ogino S, Fuchs CS, Giovannucci EL et al (2013) A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 108:1891-898 CrossRef
  52. Wu J, Cai Q, Li H, Cai H, Gao J et al (2013) Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis 34:2799-803 CrossRef
  53. Itzkowitz SH, Yio X (2004) Inflammation and cancer IV: colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17 CrossRef
  54. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS et al (2004) Comparison of risk factors for colon and rectal cancer. Int J Cancer 108:433-42 CrossRef
  55. Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403-08 CrossRef
  56. Zhou B, Liu J, Wang ZM, Xi T (2012) C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One 7:e43075 CrossRef
  57. Green J, Czanner G, Reeves G, Watson J, Wise L et al (2012) Menopausal hormone therapy and risk of gastrointestinal cancer: nested case–control study within a prospective cohort, and meta-analysis. Int J Cancer 130:2387-396 CrossRef
  
• 作者单位：Bo Zhou (1) (2)
  Bin Shu (2)
  Jue Yang (1)
  Jing Liu (2)
  Tao Xi (1)
  Yingying Xing (1)
  
  1. School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, China
  2. Jiangsu Center of Safety Evaluation for Drugs, School of Pharmaceutical Sciences, Nanjing University of Technology, Nanjing, 210009, China
  
• ISSN：1573-7225

文摘

Purpose Many studies have evaluated the associations between pre-diagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6) and colorectal cancer risk, but their results are inconsistent. We therefore conducted a meta-analysis to investigate these associations. Methods A comprehensive literature search up to October 2013 was undertaken in PubMed. Pooled relative risk (RR) estimates and 95?% confidence intervals (CIs) were used to calculate estimated effect. Results Eighteen studies on CRP comprising a total of 4,706 colorectal cancer cases were included in this meta-analysis. The summary RR of colorectal cancer for one unit change in natural logarithm (ln) CRP was 1.12 [95?% CI (1.05-.21)]. There was statistically significant heterogeneity among studies (p?=?0.006; I 2?=?51.7?%). After excluding the studies contributing most to the heterogeneity, summary estimate was essentially unchanged. In addition, the association was significant for colon cancer [RR?=?1.13, 95 % CI (1.05-.21)], not for rectal cancer [RR?=?1.03, 95 % CI (0.90-.17)]. We also found that CRP was significantly associated with increased risk of colorectal cancer among men, but not among women. There were six studies on IL-6 that involved a total of 1,068 colorectal cancer cases. The pooled RR of colorectal cancer for one unit change in ln IL-6 was 1.10 (95?% CI 0.88-.36), and no statistically significant heterogeneity was found (p?=?0.175; I 2?=?34.8?%). Conclusion Our results suggest that pre-diagnostic circulating CRP is associated with increased risk of colorectal cancer. However, there is no significant association between IL-6 and colorectal cancer risk.